Maravai LifeSciences stock gets a USD 8.00 UBS target
Published on 09/28/2026 at 15:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Maravai LifeSciences stock was last at USD 7.60 on Nasdaq on September 25, 2026 at 4:00 p.m. ET, down USD 0.05, or 0.65 percent, from the prior close of USD 7.65. The latest company presentation adds a fresh operating angle: first-half 2026 revenue rose 24 percent and adjusted EBITDA reached USD 29 million, according to TradingView News on September 25, 2026.
Revenue beat the Q2 consensus
Maravai reported USD 51.44 million in second-quarter 2026 revenue, compared with a USD 48.67 million consensus estimate, while adjusted loss per share was USD 0.02 versus an expected USD 0.04 loss. MarketBeat reported the figures for the quarter ended June 30, 2026, and also cited a negative net margin of 37.07 percent.
The comparison matters because Maravai's quarterly revenue exceeded the consensus estimate by USD 2.77 million, while the adjusted loss was USD 0.02 per share narrower than forecast. The company is therefore showing operating improvement alongside a still-negative GAAP earnings profile.
UBS lifts its target to USD 8.00
UBS raised its Maravai price target from USD 2.50 to USD 8.00 and maintained a Neutral rating on September 9, 2026, according to Yahoo Finance. The new target stands USD 0.40 above the September 25 price, giving the analyst call a defined valuation reference rather than an open-ended growth claim.
Maravai's business spans products used in vaccine, drug therapy and diagnostic development. Its portfolio includes complex nucleic acids, custom enzymes and antibody-based products, with TriLink BioTechnologies, Glen Research, Cygnus Technologies and Alphazyme among the operating brands described by Maravai LifeSciences.
MRVI remains below its yearly high
MRVI traded between USD 7.25 and USD 7.65 on September 25, 2026. Its 52-week range was USD 2.54 to USD 9.42, while market capitalization stood at USD 2.1 billion and volume reached 1,930,865 shares, putting the latest price 19.32 percent below the yearly high.
Maravai LifeSciences stock snapshot
- Company: Maravai LifeSciences Holdings, Inc.
- ISIN: US56600D1072
- Ticker: MRVI
- Trading venue: Nasdaq
- Price as of September 25, 2026 at 4:00 p.m. ET: USD 7.60
- Market capitalization: USD 2.1 billion (as of September 25, 2026)
- 52-week range: USD 2.54-USD 9.42 (as of September 25, 2026)
- Sector / Industry: Health Care / Biotechnology and medical research
More news and analysis on Maravai LifeSciences stock are available in the company topic section.
